A Phase 3 interventional study of Pegylated Interferon (PEG-IFN) alfa-2a in Hepatitis D, Chronic, sponsored by Hoffmann-La Roche. Completed at 7 sites in Romania. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-26.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Hepatitis D, Chronic with a site in Romania — 3 open to participants now, 7 under way, 3 of them phase 3. Hepatitis D, Chronic · Romania.
Among the 11 studies in Hepatitis D, Chronic with a site in Romania, this one is the only one that started in 2005, is one of 3 in phase 3, and was the 2nd registered.
43 studies on the registry are indexed under Hepatitis D, Chronic; 9 are open to participants now.
Browse Hepatitis D, Chronic studies →3 of the 11 studies in Hepatitis D, Chronic with a site in Romania are open now. Recruiting first, the newest first:
Mirum Pharmaceuticals, Inc. · Sites in Romania, Austria, Czechia and 5 more countries
Ages 18+
Gilead Sciences · Sites in Romania, United States, Bulgaria and 6 more countries
Ages 18–69 · Healthy volunteers
Assembly Biosciences · Sites in Romania, France, Georgia and 8 more countries
Ages 18–70
A study can be open while its sites in Romania have not opened yet or have stopped. Only those recruiting at a site in Romania →
Of the 6 Hepatitis D, Chronic studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 4
First in 2005; this study’s year is marked. 1 started in 2005.
This study's enrollment of 31 is below the median of 46 across 30 interventional studies indexed under Hepatitis D, Chronic.
Median enrollment 120 across the 9 interventional studies, 108 across the 2 observational. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 5 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 4 studies filed under Hepatitis D, Chronic — fewer than ten, so there is no comparison to draw.
3 of the studies in Hepatitis D, Chronic with a site in Romania that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07128550Phase 3Vir Biotechnology, Inc.A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide | 2026-12 |
| NCT07454837Phase 3Mirum Pharmaceuticals, Inc.Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide | 2027-08-31 |
| NCT07762027Assembly BiosciencesA Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 11 studies in Hepatitis D, Chronic with a site in Romania, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluated the efficacy and safety of 48-week treatment with pegylated interferon (PEG-IFN) alfa-2a (Pegasys) monotherapy in participants with chronic hepatitis D (CHD). Treatment was followed by 24 weeks of treatment-free follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 48 weeks, followed by 24 weeks of treatment-free follow-up.
Drug: Pegylated Interferon (PEG-IFN) alfa-2a
Participants received pegylated interferon (PEG-IFN) alfa-2a 180 microgram (mcg) subcutaneously (SC) weekly for 48 weeks.
Also known as: PEGASYS
Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 72
Samples were collected and analyzed for ALT. A normal ALT is a value within the normal range of the assay.
Time frame: At Week 72
Percentage of Participants With Negative Hepatitis D Virus Ribonucleic Acid (HDV RNA) at Week 72
Samples were collected and analyzed for HDV RNA levels. Negative HDV RNA is defined as below the level of detection of the assay.
Time frame: At Week 72
Percentage of Participants With Normal ALT at Week 48
Samples were collected and analyzed for ALT levels. A normal ALT is a value within the normal range of the assay.
Time frame: At Week 48
Percentage of Participants With Negative HDV RNA at Week 48
Samples were collected and analyzed for HDV RNA levels. Negative HDV RNA is defined as below the level of detection of the assay.
Time frame: At Week 48
Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Below 1*10^5 Copies/Milliliter (mL) at Weeks 48 and 72
Samples were collected and analyzed for HBV DNA levels. Reported here is the percentage of participants with HBV DNA levels below 1\*10\^5 copies/mL.
Time frame: At Weeks 48 and 72
Number of Participants With Positive Hepatitis B Surface Antigen (HBsAg) Levels
Samples were collected and analyzed for HBsAg. Positive HBsAg levels are defined as levels above the level of detection of the assay.
Time frame: At Screening and at Weeks 48 and 72
Percentage of Participants With HBsAg Seronegative at Weeks 48 and 72
Samples were collected and analyzed for HBsAg. Seronegative HBsAg is defined as below the level of detection of the assay.
Time frame: At Weeks 48 and 72
Percentage of Participants With Positive Hepatitis B Surface Antibody (HBsAb) at Weeks 48 and 72
Samples were collected and analyzed for HBsAb. Positive HBsAb levels are defined as levels above the level of detection of the assay and reflect the presence of antibodies produced against HBsAg.
Time frame: At Weeks 48 and 72
| Milestone | Pegylated Interferon (PEG-IFN) Alfa-2a |
|---|---|
| Started | 31 |
| Completed | 30 |
| Not completed | 1 |
| Withdrew: Lost to follow-up | 1 |
Samples were collected and analyzed for ALT. A normal ALT is a value within the normal range of the assay.
| percentage of participants | Pegylated Interferon (PEG-IFN) Alfa-2a |
|---|---|
| Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 72 | 54.84 (37.3 to 72.4) |
Samples were collected and analyzed for HDV RNA levels. Negative HDV RNA is defined as below the level of detection of the assay.
| percentage of participants | Pegylated Interferon (PEG-IFN) Alfa-2a |
|---|---|
| Percentage of Participants With Negative Hepatitis D Virus Ribonucleic Acid (HDV RNA) at Week 72 | 61.29 (44.1 to 78.4) |
Samples were collected and analyzed for ALT levels. A normal ALT is a value within the normal range of the assay.
| percentage of participants | Pegylated Interferon (PEG-IFN) Alfa-2a |
|---|---|
| Percentage of Participants With Normal ALT at Week 48 | 45.16 (27.6 to 62.7) |
Samples were collected and analyzed for HDV RNA levels. Negative HDV RNA is defined as below the level of detection of the assay.
| percentage of participants | Pegylated Interferon (PEG-IFN) Alfa-2a |
|---|---|
| Percentage of Participants With Negative HDV RNA at Week 48 | 64.52 (47.7 to 81.4) |
Samples were collected and analyzed for HBV DNA levels. Reported here is the percentage of participants with HBV DNA levels below 1\*10\^5 copies/mL.
| percentage of participants | Pegylated Interferon (PEG-IFN) Alfa-2a |
|---|---|
| HBV-DNA at Week 48 | 83.87 (70.9 to 96.8) |
| HBV-DNA at Week 72 | 74.19 (58.8 to 89.6) |
Samples were collected and analyzed for HBsAg. Positive HBsAg levels are defined as levels above the level of detection of the assay.
| participants | Pegylated Interferon (PEG-IFN) Alfa-2a |
|---|---|
| HBsAg Positive at Screening | 31 |
| HBsAg Positive at Week 48 | 29 |
| HBsAg Positive at Week 72 | 26 |
Samples were collected and analyzed for HBsAg. Seronegative HBsAg is defined as below the level of detection of the assay.
| percentage of participants | Pegylated Interferon (PEG-IFN) Alfa-2a |
|---|---|
| Seronegative HBsAg at Week 48 | 0 (NA to NA) |
| Seronegative HBsAg at Week 72 | 3.23 (0.0 to 9.4) |
Samples were collected and analyzed for HBsAb. Positive HBsAb levels are defined as levels above the level of detection of the assay and reflect the presence of antibodies produced against HBsAg.
| percentage of participants | Pegylated Interferon (PEG-IFN) Alfa-2a |
|---|---|
| Positive HBsAb at Week 48 | 3.23 (0.0 to 9.4) |
| Positive HBsAb at Week 72 | 3.23 (0.0 to 9.4) |
Collected over Up to week 72. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pegylated Interferon (PEG-IFN) Alfa-2a | — | — | — |
| Age, Continuous(years) | Pegylated Interferon (PEG-IFN) Alfa-2a |
|---|---|
| Mean | 38 ± 13.3 |
| Sex: Female, Male(Participants) | Pegylated Interferon (PEG-IFN) Alfa-2a |
|---|---|
| Female | 10 |
| Male | 21 |
The record gives a start of Oct 2005, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 7 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2a